Brief: Pledpharma Changes Its Name To Egetis Therapeutics With Focus On Late Stage Orphan Drug Development
Dec 17 (Reuters) - PledPharma AB (publ) PLED.ST :
* PLEDPHARMA CHANGES ITS NAME TO EGETIS THERAPEUTICS WITH FOCUS ON LATE STAGE ORPHAN DRUG
DEVELOPMENT
* PLEDPHARMA AB (PUBL) - CHANGE IS A RESULT OF ACQUISITION OF RARE THYROID THERAPEUTICS AB
Source text for Eikon: ID:nMFNbDxRX
Further company coverage: PLED.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1